Get Permission Kshirsagar, Thakar, Dalal, Babu, Modak, and Kumar: Candidemia in a tertiary care hospital: Changing trends


Introduction

Candida species are normal inhabitants of skin and mucosa.1 It can become pathogenic in situations where the host defences are disturbed. Risk factors include immunocompromised conditions like diabetes mellitus, prolonged use of steroids, long term use of antibiotics, old age, presence of indwelling devices and recent gastrointestinal surgery1, 2 Candida can cause various clinical manifestations like oropharyngeal candidiasis, vulvovaginal candidiasis, genitourinary candidiasis and blood stream infections.3 Over the past two decades, blood stream infections (BSI) caused by Candida species are increasing. Prevalence of candidemia in India (2020) ranges from 1.31%- 3.41%.4, 5 Although Candida albicans was considered as the most common species causing candidemia, BSI caused by Non-albicans Candida(NAC) species like C. tropicalis & C. parapsilosis (in developing countries) and C. glabrata (in developed nations)are emerging as a major cause of nosocomial infections.5, 6 Increased morbidity and prolonged hospital stay are associated with invasive candidiasis resulting in mortality. Mortality associated with candidemia is estimated to be 19–24% by CDC.7

Fluconazole is the most commonly used antifungal for the treatment of candidemia. Candida krusei is intrinically resistant to fluconazole. Other NAC species like, Candida guilliermondii, C.glabrata C. inconspicua are less susceptible to azoles. Though resistance to echinocandins is considered rare, it is also on the rise. Intrinsic and acquired resistance to various antifungals is becoming a major problem in treatment of candidemia.2 Therefore it is important to identify the Candida species causing sepsis and determine their antifungal susceptibility pattern to select the right antifungal giving appropriate coverage. This will help in effective management of these patients, thus reducing mortality caused by Candida and also to control outbreaks.8 This study was undertaken to find out prevalence of candida species causing sepsis and its outcome in a tertiary care hospital.

Materials and Methods

Study design

Descriptive cross-sectional study.

Study period

July 2021 to June 2023.

Place of study

Department of Microbiology, tertiary care hospital, Pune

Methodology

All the blood samples received during the study period and which grew Candida species were included in the study. Blood cultures which grew organisms other than Candida species were excluded from the study. Blood samples of patients with suspected candidemia were received in automated blood culture bottles (BD BACTECFX 40) and were incubated in the automated BD BACTEC TM FX (Becton, Dickinson and Company, NJ, and USA). Once the bottle flagged positive, Gram stain was done and presence of gram positive budding yeast cells was recorded. Gram’s staining findings were immediately communicated to clinician for early start of antifungal therapy. Candida species were identified by routine conventional methods like growth on blood agar (Figure 1), SDA (Sabouraud Dextrose Agar), germ tube test, CHROM agar Candida (HiMedia, Mumbai, India) (Figure 2) and automated identification system (VITEK 2 compact - BioMérieux, France). In vitro antifungal susceptibility profile was determined by the automated antifungal susceptibility system (VITEK 2 BioMérieux, France). Demographic and clinical details of the patients were collected.

Statistical analysis

The collected data was entered in Microsoft excel sheet and analysed. Data presented as numbers and percentages.

Results

A total of 4367 blood cultures were received during the study period. Of this, 131(2.99%) grew Candida species. 36 (out of the 131) isolates were obtained from children below one year of age (Table 1). Majority {91 of 131 (69.4%)} of the patients were admitted in critical care units (ICUs) (Figure 3), out of which (45) 34.35% were adults, while (46)35.1% were children below 10 years. Male and female patients were equally affected. Majority of the patients had associated co-morbidities like diabetes mellitus, malignancy, chronic kidney disease (Table 2). C. parapsilosis was isolated from 42 samples (32%), followed by C. tropicalis 38 (29%) , C. albicans 30 (22.9%), C.guilliermondi 07 (5.34%), C.glabrata 06 (4.58%), C.krusei 05 (3.8) and C.lusitaniae 01 (0.78) (Figure 4). Antifungal susceptibility pattern of the Candida isolates showed that 73.2% were susceptible to fluconazole, 88.5% to voriconazole, 90% to caspofungin, 92.3% to micafungin, 81.6% to amphotericin B and 100% to flucytosine (Figure 5). A total of 16.6% of C.parapsilosis strains were resistant to fluconazole, voriconazole and amphotericin B while 7.4% were resistant to caspofungin and micafungin. Seventeen (44.7%) C.tropicalis strains were resistant to fluconazole, 7 (18.4%) were resistant to amphotericin B and voriconazole while 4(10.5% ) were resistant to caspofungin and micafungin each. C.albicans strains were fully susceptible to all antifungal agents except (n=4)13.3% of strains which were resistant to fluconazole (Table 3) Antifungal susceptibility testing of Candida auris isolates could not be performed.

Follow up

Twenty two (16.79%) patients succumbed to candidemia (Table 4). All others responded to azole group of drugs. Two patients infected with Candida auris were treated with echinocandins. Contact precautions were followed while handling these patients.

Figure 1

Growth of Candida on blood agar

https://s3-us-west-2.amazonaws.com/typeset-prod-media-server/2ce0176a-e822-4362-9b7b-368a340300d0image1.png
Figure 2

CHROM agar

https://s3-us-west-2.amazonaws.com/typeset-prod-media-server/2ce0176a-e822-4362-9b7b-368a340300d0image2.png
Table 1

Age wise distribution of patients

Age group (in years)

Number of patients

0-1

36

1-10

09

11-20

08

21-30

07

31-40

13

41-50

30

51-60

15

61-70

07

71-80

06

>80

0

Total

131

Figure 3

Location of patients

https://s3-us-west-2.amazonaws.com/typeset-prod-media-server/2ce0176a-e822-4362-9b7b-368a340300d0image3.png
Table 2

Associated Co-morbidities

Co-morbidities associated

Number of patients with risk factors

Diabetes mellitus

40

Chronic kidney disease

20

Malignancy

25

Prolonged use of broad spectrum antibiotic

90

Prolonged stay in ICU/NICU ( >1 month)

30

Total parenteral nutrition

20

Premature neonates with respiratory distress

25

Presence of CVC

28

[i] Abbreviations used: NICU- Neonatal ICU, PICU- Paediatric ICU

Figure 4

Isolated candida species

https://s3-us-west-2.amazonaws.com/typeset-prod-media-server/2ce0176a-e822-4362-9b7b-368a340300d0image4.png
Figure 5

Antifungal susceptibility pattern of all Candida isolates

https://s3-us-west-2.amazonaws.com/typeset-prod-media-server/2ce0176a-e822-4362-9b7b-368a340300d0image5.png

Table 3

Antifungal resistance in different Candia species

*100% susceptible to Flucytosine

Candida species

Fluconazole

Voriconazole

Caspofungin

Micafungin

Amphotericin B

C. albicans

4

0

0

0

0

C. parapsilosis

7

7

3

3

7

C. tropicalis

17

7

4

4

7

C. guilliermondi

3

1

2

2

2

C. krusei

5IR

0

0

0

5

C.glabrata

4

0

4

1

3

C. lusitaniae

0

0

0

0

0

[i] Abbreviations used- IR: Intrinsic resistance

Table 4

Candida species isolated from patients who expired due to candidemia

Candida species isolated

Number of patients

C. parapsilosis

9

C.tropicalis

7

C.glabrata

4

C.albicans

1

C.guilliermondii

1

Discussion

Over the recent years, Candida has emerged as a major cause of blood stream infections. In the United States, Candida species have been found to be the fourth most common cause of blood stream infections.9 Candida ranks among the top ten pathogens responsible for hospital acquired blood stream infections.2 A study by Chakrabarti A has found that the rate of candidemia in developing countries is 4-15 times more than in developed countries.10 The prevalence of candidemia was found to be 2.99 % in our study. The prevalence of candidemia was found to be 3.4% by Ahmed S et al in Uttar Pradesh, 1.3% by Kaur H et al in Chandigarh (North India), 1.4% by Jain V et al in Rajasthan (Western India), 3.8% by Behera C et al in Bhubaneswar (Eastern India) and 0.65% by Giri S et al in Tamil Nadu (South India).4, 5, 11, 12, 13 In our study, 27.4% of the population was below 1 year of age. As per Mantadakis E et al, candidemia is several times more common in infants and neonates than in adults .Main risk factors associated with candidemia in children were respiratory diseases, prematurity, ICU admission, mechanical ventilation, neutropenia, and malignancy. 14 In our study comorbidities associated with candidemia in neonates were prematurity and respiratory distress syndrome. All the children were admitted in critical care units. In the present study the risk factors in adults were diabetes mellitus, chronic kidney disease and malignancy. In the study of Blyth et al., renal disease, recent surgery, diabetes mellitus and haemodialysis were the frequent risk factors in adults.15 Underlying conditions like renal insufficiency, trauma, gastrointestinal perforation, prolonged use of broad spectrum antibiotics, stay in ICU or use of central venous catheter were predisposing factors in a study done by Capoor MR et al. 16 It has been observed that candidemia is more common in diabetic patients because of the adhesion of yeast to host epithelium, high serum glucose levels as compared to healthy individuals, poor candidacidal activity of neutrophils and microvascular degeneration. 17 In present study, 19.0% (25) had history of malignancy. Presence of central venous catheter or parenteral nutrition were the reason for development of candidemia in patients with hematologic malignancies in a study by Girmenia C et al.18

In India, a change in trend of species causing candidemia in the recent years from C albicans to NAC 6 has been observed. Along with C albicans, other NAC species like C. parapsilosis, C.krusei, C. tropicalis and C. glabrata contribute to 92% of cases candidemia globally. Candida glabrata is common in elderly patients and Candida albicans is more common in children upto 18 years of age. 19 Candida auris which was considered a rare pathogen previously is also becoming a prominent pathogen. 20 This shift could be due to better detection rate of NAC or as a result of rampant use of fluconazole for treatment of all fungal infections resulting in shift in the colonisation and infection with fluconazole resistant strains like C. krusei. 21, 22, 23, 24, 25, 26, 27, 28 In our study, Candida parapsilosis was the commonest species (32%) which correlated with the studies undertaken by Shivprakash et al (28.8%) and Capoor et al. (27.4%).6, 16 Low prevalence of C. parapsilosis was reported in studies conducted by Sridharan et al (17%) and Bhattacharje et al (17%) and Amir et al (8%).28, 22, 27

Fluconazole is the preferred antifungal for treatment of less severe infections while echinocandins are preferred for moderate to severe infections or in systemic candidiasis as per the guidelines from the Infectious Diseases Society of America. 2 Fluconazole being the most frequently used antifungal, its resistance is on the rise in many parts of the world. 4 Various studies have reported resistance to fluconazole i.e 10% by Seyoum E et al in Ethiopia(2020),15% by Bilal H et al in China (2022), 5% by Bedini A et al in Italy(2006) and 34.8% by Bhattacharjee P et al in India(2016).21, 22, 23, 24 In the present study 26.7% of the isolates were resistant to fluconazole. This is slightly higher than other studies as candidemia caused by NAC was more common in this study. Many species of candida are intrinsically resistant to many antifungals. C. auris is intrinsically resistant to polyenes and fluconazole while C. krusei is intrinsically resistant to fluconazole. Empiric antifungal therapy is usually given in febrile neutropenia patients who do not respond to antibiotic therapy and in cases of perforated peritonitis. This has led to the development of acquired resistance to many antifungals especially the azoles. Mechanisms by which azoles develop resistance are over expression of membrane transporters, alteration of ergosterol biosynthesis, sterol import alteration and genome plasticity. 25

Hand hygiene, isolation of patient, environmental disinfection and avoiding unnecessary use of broad spectrum antibiotics are measures by which candidemia can be controlled to an extent. If the patient is on central venous catheter, it must be regularly monitored for signs of infection. 26

Conclusion

The prevalence of candidemia was found to be 2.99%, with an increasing trend of bloodstream infections caused by non-albicans Candida (NAC) species. Most cases occurred in patients admitted in critical care units. Commonly isolated species were Candida parapsilosis and Candida tropicalis, many of which showed resistance to the commonly used antifungal fluconazole. The recent emergence of Candida auris has further complicated the treatment of candidemia. Rapid diagnosis, early treatment, strict infection control measures, and robust antimicrobial stewardship practices are essential to reduce the burden of candidemia.

Ethical Approval

This study was approved by the institutional Ethical Committee (Approval number-BVDUMC/IEC/263).

Conflict of Interest

None.

Source of Funding

None.

References

1 

V Mohandas M Ballal Distribution of Candida species in different clinical samples and their virulence: biofilm formation, proteinase and phospholipase production: a study on hospitalized patients in southern IndiaJ Glob Infect Dis20113148

2 

M Sanguinetti B Posteraro Lass-Flörl C. Antifungal drug resistance among Candida species: mechanisms and clinical impactMycoses2015582213

3 

TE Zaoutis J Argon J Chu JA Berlin TJ Walsh C Feudtner The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: a propensity analysisClin Infect Dis200541912329

4 

S Ahmed M Shahid N Fatima F Khan U Tayyaba Candidemia – Changing Trends from Candida albicans to Non-Albicans Candida from a Tertiary Care Center in Western UP, IndiaCHRISMED J Health Res20207316772

5 

H Kaur S Singh S M Rudramurthy A K Ghosh M Jayashree Y Narayana Candidaemia in a tertiary care centre of developing country: Monitoring possible change in spectrum of agents and antifungal susceptibilityIndian J Med Microbiol202038110916

6 

S Shivaprakasha K Radhakrishnan P M Karim Candida spp. other than Candida albicans: a major cause of fungaemia in a tertiary care centreIndian J Med Microbiol20072544057

7 

J Morgan MI Meltzer BD Plikaytis AN Sofair S Huie-White S Wilcox Excess mortality, hospital stay, and cost due to candidemia: a case-control study using data from population-based candidemia surveillanceInfect Control Hospital Epidemiol20052665407

8 

K Montes B Ortiz C Galindo I Figueroa S Braham G Fontecha Identification of Candida Species from Clinical Samples in a Honduran Tertiary HospitalPathogens20198423710.3390/pathogens8040237

9 

M Morrell VJ Fraser MH Kollef Delaying the empiric treatment of candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortalityAntimicrob Agents Chemother200549936405

10 

A Chakrabarti Fungal Infections in Asia: Eastern Frontier of MycologyElsevierIndia2014

11 

V Jain T Nare K Vishwakarma A Kundu A Radhkrishnan V Tak P049 Candidemia: Isolate profiling and antifungal susceptibility testing experience from Jodhpur, Western IndiaMed Mycol2022601myac072P04910.1093/mmy/myac072.P049

12 

C Behera R Mishra PK Jena S Mishra B Sahoo SB Patnaik Candidemia in the pediatric intensive care unit in Eastern IndiaJ Pediatr Crit Care20207523742

13 

S Giri AJ Kindo J Kalyani Candidemia in intensive care unit patients: A one year study from a tertiary care center in South IndiaJ Postgrad Med20135931905

14 

E Mantadakis ZD Pana T Zaoutis Candidemia in children: Epidemiology, prevention and managementMycoses201861961422

15 

CC Blyth SC Chen MA Slavin Not just little adults: candidemia epidemiology,molecular characterization, and antifungal susceptibility in neonatal and pediatric patientsPediatrics2009123513608

16 

MR Capoor D Nair M Deb PK Verma L Srivastava P Aggarwal Emergence of non-albicans Candida species and antifungal resistance in a tertiary care hospitalJpn J Infect Dis20055863448

17 

C F Rodrigues M E Rodrigues M Henriques Candida Infections in Patients with Diabetes MellitusJ Clin Med20198176

18 

C Girmenia P Martino F De Bernardis G Gentile M Boccanera M Monaco Antonucci Rising incidence of Candida parapsilosis fungemia in patients with hematologic malignancies: clinical aspects, predisposing factors, and differential pathogenicity of the causative strainsClin Infect Dis199623350614

19 

J Guinea Global trends in the distribution of Candida species causing candidemiaClin Microbiol Infect1920206510

20 

PG Pappas MS Lionakis MC Arendrup L Ostrosky-Zeichner BJ Kullberg Invasive candidiasisNat Rev Dis Primers201841802610.1038/nrdp.2018.26

21 

E Seyoum A Bitew A Mihret Distribution of Candida albicans and non-albicans Candida species isolated in different clinical samples and their in vitro antifungal suscetibity profile in EthiopiaBMC Infect Dis202020123110.1186/s12879-020-4883-5

22 

P Bhattacharjee Epidemiology and antifungal susceptibility of Candida species in a tertiary care hospitalCurr Med Mycol201622207

23 

H Bilal B Hou M Shafiq X Chen MA Shahid Y Zeng Antifungal susceptibility pattern of Candida isolated from cutaneous candidiasis patients in eastern Guangdong region: A retrospective study of the past 10 yearsFront Microbiol20221398118110.3389/fmicb.2022.981181

24 

A Bedini C Venturelli C Mussini G Guaraldi M Codeluppi V Borghi Epidemiology of candidaemia and antifungal susceptibility patterns in an Italian tertiary-care hospitalClin Microbiol Infect20061217580

25 

S Bhattacharya S Sae-Tia B C Fries Candidiasis and Mechanisms of Antifungal ResistanceAntibiotics (Basel)20099631210.3390/antibiotics9060312

26 

GM Snyder SB Wright The Epidemiology and Prevention of Candida aurisCurr Infect Dis Rep20192161910.1007/s11908-019-0675-8

27 

A Arastehfar S Yazdanpanah M Bakhtiari W Fang W Pan S Mahmoudi Epidemiology of candidemia in Shiraz, southern Iran: A prospective multicenter study (2016–2018) Get access ArrowMed Mycol201659542230

28 

S Sridharan R Gopalakrishnan P S Nambi S Kumar N Sethuraman V Ramasubramanian Clinical Profile of Non-neutropenic Patients with Invasive Candidiasis: A Retrospective Study in a Tertiary Care CenterIndian J Crit Care Med202125326772PMCID



jats-html.xsl


This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

  • Article highlights
  • Article tables
  • Article images

Article History

Received : 09-07-2024

Accepted : 08-08-2024


View Article

PDF File   Full Text Article


Copyright permission

Get article permission for commercial use

Downlaod

PDF File   XML File   ePub File


Digital Object Identifier (DOI)

Article DOI

https://doi.org/10.18231/j.ijmmtd.2024.040


Article Metrics






Article Access statistics

Viewed: 170

PDF Downloaded: 66



Medical Abbreviation List